OKYO OKYO Pharma

OKYO Pharma Limited - Upcoming Presentation

OKYO Pharma Limited - Upcoming Presentation

LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that Kunwar Shailubhai, Ph.D., the Company’s CEO, will share insight into OKYO’s development pipeline and upcoming milestones during an investor webinar, hosted by RedChip Companies, on Sunday, August 2, 2020. A live Q&A session with Dr. Shailubhai will follow the presentation. A link to a recording of the presentation will be provided on Monday morning via RNS Reach.

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma LimitedWilly Simon+44 (0)20 7495 2379
Optiva Securities Limited

Robert Emmet+44 (0)20 3981 4173

For further information, please visit the Company's website at

EN
31/07/2020

Underlying

OKYOOKYO Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OKYO Pharma

 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Chief Development Officer and Director Acquires ...

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urc...

March 19, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvem...

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod (0.05%) for the treatment o...

March 18, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Abstract Selected for Presentation at Premier Global Ophthalmolog...

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will share...

February 23, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordina...

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ord...

February 13, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Public Offering of Ordinary Shares

OKYO Pharma Announces Public Offering of Ordinary Shares LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the “Offering”). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the ...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch